Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA.

@article{Granstein2000InductionOA,
  title={Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA.},
  author={Richard D. Granstein and Wanhong Ding and Hiroaki Ozawa},
  journal={The Journal of investigative dermatology},
  year={2000},
  volume={114 4},
  pages={
          632-6
        }
}
The skin is well-suited to serve as a substrate for vaccination strategies. In this regard, epidermal cells exposed to granulocyte-macrophage colony-stimulating factor can, upon subcutaneous injection into naïve mice, present a soluble extract of tumor as a source of tumor-associated antigens for the induction of in vivo anti-tumor immunity. Use of RNA for immunization has a potential advantage over this technique. Because RNA can be amplified, only a small amount of tumor is needed for antigen… 
RNA as a tumor vaccine: a review of the literature
TLDR
The possible utility of RNA‐based vaccines for tumor immunotherapy should be further explored to determine whether such approaches are clinically useful.
Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients
TLDR
It is shown here that direct injection of protamine-protected mRNA is feasible and safe and the significant influence of the treatment on the frequency of immunosuppressive cells, the increase of vaccine-directed T cells upon treatment in a subset of patients together with the demonstration of a complete clinical response encourage further clinical investigation of the protamines-mRNA vaccine.
Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization.
TLDR
PPI elicited neither local nor systemic toxicity or autoimmunity, except for vitiligo, in patients with melanoma, therefore, PPI represents a novel therapeutic intervention for cancer in the clinical setting.
Intranasal vaccination with messenger RNA as a new approach in gene therapy: Use against tuberculosis
TLDR
Vaccination of mice with a single dose of naked mRNA-Hsp65 through intranasal route was able to induce protection against subsequent challenge with virulent strain of Mycobacterium tuberculosis, showing a novel and efficient strategy to control experimental tuberculosis.
mRNA: delivering an antitumor message?
TLDR
This study highlights the potential of mRNA vaccines to induce immune responses and mediate sustained antitumor activity in both prophylactic and therapeutic settings.
RNA based vaccines.
TLDR
In this article, immune responses developed, interactions between APC and RNA that activate and dictate DC activation, and preliminary studies using RNA in vivo and in vitro to develop protective immunity are discussed.
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
TLDR
It is demonstrated here that such treatment is feasible and safe (phase 1 criteria) and an increase in antitumor humoral immune response was seen in some patients, however, a demonstration of clinical effectiveness of direct injection of copy mRNA for antitumors immunotherapy was not shown in this study and must be evaluated in subsequent trials.
Cancer immunotherapy with mRNA‐transfected dendritic cells
TLDR
Immunization with mRNA‐transfected DCs is a promising strategy to stimulate potent antitumor immunity and could serve as a foundation for developing effective treatments for cancer.
New approaches using genetic material as a control to tuberculosis
TLDR
The results showed a novel and promise strategy to control experimental tuberculosis through vaccination of mice with a single dose of naked mRNA-Hsp65 through intranasal route was able to induce protection against subsequent challenge with virulent strain of M. tuberculosis.
...
...

References

SHOWING 1-10 OF 15 REFERENCES
Tumor antigen presentation by murine epidermal cells.
TLDR
I-A+ epidermal cells are capable of presenting S1509a tumor Ag for the generation of protective antitumor immunity in vivo and to immunize for a significant delayed-type hypersensitivity response to injected tumor cells.
Interleukin 1α but Not Transforming Growth Factor β Inhibits Tumor Antigen Presentation by Epidermal Antigen-Presenting Cells
TLDR
Investigating whether locally produced cytokines may be able to down-regulate the presentation of tumor-associated antigens and alloantigen by epidermal antigen-presenting cells in primed as well as in unprimed systems found interleukin-1α may be an important regulator of Langerhans cell antigenpresenting function.
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
TLDR
The finding that RNA transcribed in vitro from cDNA cloned in a bacterial plasmid was highly effective in sensitizing DC shows that amplification of the antigenic content from a small number of tumor cells is feasible, thus expanding the potential use of RNA-pulsed DC- based vaccines for patients bearing very small, possibly microscopic, tumors.
Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
TLDR
Dendritic cells generated from the peripheral blood mononuclear cells of healthy individuals or from cancer patients transfected with carcinoembryonic antigen (CEA) mRNA stimulate a potent CD8+ cytotoxic T lymphocyte response in vitro, providing a general method for inducing, as well as measuring, CEA-specific CTL responses across a broad spectrum of HLA haplotypes.
IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells.
TLDR
IL-10 appears to specifically prevent the GM-CSF-induced maturation of LC Ag-presenting function when treatment with IL-10 occurs before exposure to GM- CSF but does not reverse the established mature state.
Interferon‐γ inhibits tumor antigen presentation by epidermal antigen‐presenting cells
TLDR
The results show that three weekly subcutaneous injections of naive mice with GM‐CSF‐cultured but not with fresh TAA‐pulsed epidermal APCs induce protective tumor immunity in naive mice and that the immunostimulatory effect of GM‐ CSF in this system is abrogated by coculture of epidersmal cells in IFN–γ.
Tumor antigen presentation by epidermal antigen‐presenting cells in the mouse: modulation by granulocyte‐macrophage colony‐stimulating factor, tumor necrosis factor α, and ultraviolet radiation
TLDR
Results demonstrate that GM‐CSF, TNF‐α, and UVR are significant regulators of tumor antigen presentation by epidermal APCs and that the effects of the cytokines examined differ with regard to induction or elicitation of immunity.
Immunosuppressor T cells in tumor bearing host.
TLDR
Thymus or spleen cells of tumor bearing animals (TBA) (methylcholanthrene induced sarcoma bearing A/Jax mice) were shown to possess immunosuppressor cells regulating the immune response to the tumor in syngeneic animals, which may be largely responsible for the growth of antigenic tumors.
Regulation of tumor antigen presentation by urocanic acid.
TLDR
Data indicate that cis-UCA may be an important regulator of LC Ag-presenting function in tumor-immune responses, and thus may play a role in photocarcinogenesis.
Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells
TLDR
The results suggest that dendritic cells in nonlymphoid tissues like skin can act as sentinels for presenting antigens in situ, their accessory function developing in two phases.
...
...